<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284647</url>
  </required_header>
  <id_info>
    <org_study_id>2010-081</org_study_id>
    <nct_id>NCT01284647</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Double-dummy, Sucralfate Controlled, Multicenter Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai China Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of teprenone on chronic non-atrophic
      erosive gastritis and its therapeutic mechanism
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference of the modified Lanza score after 4 weeks of treatment between teprenone group and sucralfate group</measure>
    <time_frame>0,4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference of total effective rate after 4 weeks treatment evaluated by histologic examination on inflammation improvement between teprenone group and sucralfate group</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference of patients' gastric mucosal concentration of hexosamine, PGE2 and HSP70 after 4 weeks treatment between teprenone group and sucralfate group</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference of total effective rate after 4 and 8 weeks treatment evaluated by clinical symptom score between teprenone group and sucralfate group</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference of total effective rate after 8 weeks treatment evaluated by endoscopy between teprenone group and sucralfate group</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Chronic Erosive Gastritis</condition>
  <arm_group>
    <arm_group_label>Teprenone capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sucralfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teprenone capsule and placebo of sucralfate</intervention_name>
    <description>Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.</description>
    <arm_group_label>Teprenone capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sucralfate and placebo of teprenone</intervention_name>
    <description>Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks</description>
    <arm_group_label>sucralfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-65 years old

          2. Have been diagnosed as chronic non-atrophic erosive gastritis by endoscopy within 1
             weeks before enrollment, and the modified Lanza score ≥ 2

          3. Have at least two symptoms in four major symptoms (epigastric pain, epigastric
             burning, early satiety, belching) and total symptom score ≥ 4 (Rome Ⅲ for Functional
             Gastrointestinal Disorders)

        Exclusion Criteria:

          1. Suspected upper gastrointestinal malignancy by endoscopy

          2. Peptic ulcer and bleeding by endoscopy

          3. Severe cardiac, hepatic or renal insufficiency

          4. Severe neurological or psychological disease

          5. Pregnant or lactating women

          6. Have taken drugs which may affect evaluating the efficacy of study drug within two
             weeks before enrollment (includes but not limits to: Proton pump inhibitors such as
             omeprazole, rabeprazole, pantoprazole, lansoprazole, esomeprazole, H2 receptor
             antagonists such as cimetidine, ranitidine, famotidine, antacids such as calcium
             carbonate, gastric mucosal protectants such as colloidal bismuth potassium citrate and
             other bismuth products, sucralfate, aluminum phosphate, teprenone, gefarnate, aluminum
             magnesium carbonate, glutamine, rebamipide, ecabet, misoprostol, antibiotics such as
             amoxicillin, clarithromycin, tetracycline, ofloxacin, levofloxacin, furazolidone,
             metronidazole, tinidazole, Non-Steroid Anti-Inflammatory Drugs such as aspirin,
             ibuprofen, loxoprofen, naproxen, diclofenac, indomethacin, meloxicam, acetaminophen)

          7. History of allergic reaction to the medications used in this study

          8. Patients that investigators consider ineligible for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoshen Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Yinchun Zhang</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Chronic Erosive Gastritis</keyword>
  <keyword>Teprenone</keyword>
  <keyword>Sucralfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sucralfate</mesh_term>
    <mesh_term>Geranylgeranylacetone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

